Advertisement
Organisation › Details
DCPrime B.V.
DCPrime is a privately owned, clinical stage biotechnology company focused on developing therapeutic, dendritic cell-based cancer vaccines. DCPrime’s technology platform is based on the DCOne® cell line, which is derived from myeloid leukemia cells and expresses a number of validated tumor antigens. This makes the platform suitable for application in patients with myeloid and other hematological cancers. In addition, DCOne® cells can be loaded with tumor associated antigens of choice, to develop cancer-specific vaccine formulations for multiple other (solid) cancer types. The company’s lead product DCP-001 is positioned as a consolidation vaccine therapy in Acute Myeloid Leukemia (AML). A Phase I/IIa study with this product has been completed and shows that DCP-001 is a safe product that induces a clear anti-tumor response in patients, and strong survival improvement in several of the studied patients. DCPrime received orphan drug designation in AML for this product from the EMA and is currently preparing a multi-center Phase II trial to demonstrate efficacy in AML patients. *
Start | 2005-03-01 splitoff | |
End | 2022-06-23 renamed | |
Group | Mendus (Group) | |
Today | Mendus B.V. | |
Predecessor | Free University of Amsterdam (Vrije Universiteit Amsterdam) (VU) | |
Successor | Mendus B.V. | |
Industry | therapeutic vaccine | |
Industry 2 | DCP-001 cancer vaccine (DCPrime) | |
Person | Manting, Erik (Immunicum AB 202110 before CEO of DCPrime) | |
Person 2 | Kruisbeek, Ada (DCPrime BV 201710 CEO + CSO + Founder) | |
Region | Leiden | |
Country | Netherlands | |
Street | 8 Galileiweg Leiden Bio Science Park | |
City | 2333 BD Leiden | |
Tel | +31-71-332-2627 | |
Address record changed: 2022-04-28 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Apceth Biopharma GmbH. (10/19/17). "Press Release: DCPrime and Apceth Biopharma GmbH Announce Manufacturing Partnership". Leiden & Munich. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Mendus (Group)
- [1] Immunicum AB. (10/26/21). "Press Release: Immunicum Appoints Lotta Ferm as Chief Financial Officer"....
- [2] Elicera Therapeutics AB. (3/22/21). "Press Release: Elicera Announces Appointment of ATMP Specialist Karin Hoogendoorn to the Board". Gothenburg....
- [3] Immunicum AB. (11/18/20). "Press Release: Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies"....
- [4] Glycotope GmbH. (9/21/20). "Press Release: DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms". Leiden & Berlin....
- [5] Immunicum AB. (12/13/19). "Press Release: Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO"....
- [6] Apceth Biopharma GmbH. (11/16/18). "Press Release: Apceth Biopharma GmbH Manufactures DCprime’s Cell-based Cancer Vaccine for Phase II Clinical Study". Munich....
- [7] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy [Not for US, AU, CA, et al...
- [8] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Clarifies Information Regarding Directed Issue [Not for US, AU, CA, et al.]"....
- [9] Immunicum AB. (10/16/18). "Press Release: Notice of Extraordinary General Meeting in Immunicum AB (publ)"....
- [10] Immunicum AB. (9/27/18). "Press Release: Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top